0000914190-21-000195.txt : 20210714 0000914190-21-000195.hdr.sgml : 20210714 20210714165714 ACCESSION NUMBER: 0000914190-21-000195 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210712 FILED AS OF DATE: 20210714 DATE AS OF CHANGE: 20210714 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hippel James CENTRAL INDEX KEY: 0001603594 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 211090735 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-07-12 0000842023 BIO-TECHNE Corp TECH 0001603594 Hippel James 614 MCKINLEY PLACE N.E. MINNEAPOLIS MN 55413 0 1 0 0 Chief Financial Officer Common Stock 2021-07-12 4 M 0 10000 106.59 A 19137 D Common Stock 2021-07-12 4 S 0 600 451.0665 D 18537 D Common Stock 2021-07-12 4 S 0 751 451.9519 D 17786 D Common Stock 2021-07-12 4 S 0 788 453.2053 D 16998 D Common Stock 2021-07-12 4 S 0 662 454.1497 D 16336 D Common Stock 2021-07-12 4 S 0 1773 455.5653 D 14563 D Common Stock 2021-07-12 4 S 0 527 456.4078 D 14036 D Common Stock 2021-07-12 4 S 0 1136 457.7947 D 12900 D Common Stock 2021-07-12 4 S 0 1863 458.814 D 11037 D Common Stock 2021-07-12 4 S 0 800 459.6398 D 10237 D Common Stock 2021-07-12 4 S 0 600 460.7133 D 9637 D Common Stock 2021-07-12 4 S 0 300 462.0843 D 9337 D Common Stock 2021-07-12 4 S 0 100 463.56 D 9237 D Common Stock 2021-07-12 4 S 0 100 466.44 D 9137 D Stock Options (Right to Buy) 106.59 2021-07-12 4 M 0 10000 0 D 2023-08-18 Common Stock 10000 20000 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 24460 24460 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 32613 32613 D Restricted Stock Units Common Stock 3383 3383 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 18066 18066 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 24089 24089 D Restricted Stock Units Common Stock 3938 3938 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 19936 19936 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 26581 26581 D Restricted Stock Units Common Stock 3219 3219 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 14360 14360 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 19147 19147 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 8325 8325 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 8325.0 8325.0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.48 to $451.44, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.59 to $452.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $452.69 to $453.68, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $453.76 to $454.74, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $455.00 to $455.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $456.16 to $456.65, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $457.19 to $458.18, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $458.29 to $459.26, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $459.34 to $460.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $460.39 to $461.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $461.71 to $462.60, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. Fully exercisable. Options to purchase 8,153 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and options to purchase 8,154 shares vest on 8/9/2021. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,023 shares vest on 8/8/2019 and options to purchase 6,022 shares vest on each of 8/8/2020, 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. /s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed. 2021-07-14